News

Fund+ in the news
February 18, 2021

Immunic, Inc. Announces Positive Top-Line Data From Investigator- Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Immunic, Inc. Announces Positive Top-Line Data From Investigator- Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis – Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared to Baseline – – Primary Objective of Therapeutic Benefit Achieved in 27.3% of the Patients […]

Read Post
February 18, 2021

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial Clinical Activity of IMU-838 Confirmed Based on Multiple Secondary Endpoints, Including Clinically Meaningful Improvements in Time to Clinical Recovery and Clinical Improvement – Primary and Key Secondary Endpoints Were Not Evaluable Due to the Very […]

Read Post
February 17, 2021

Minoryx Therapeutics in the news

Minoryx Therapeutics in the news

Read Post
January 27, 2021

Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN)

Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN) • Largest prospective efficacy study conducted in the orphan disease AMN • Leriglitazone significantly reduces progression of cerebral lesions and myelopathy symptoms • Minoryx preparing for discussions with regulators for approval of leriglitazone for AMN patients Mataró, […]

Read Post
December 18, 2020

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia   Study demonstrates leriglitazone improves relevant disease biomarkers and ataxia resulting in clinical benefit in this orphan disease   Mataró, Barcelona, Spain, December 15, 2020 – Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on […]

Read Post
December 14, 2020

Immunic, Inc. Added to NASDAQ Biotechnology Index

Immunic, Inc. Added to NASDAQ Biotechnology Index   NEW YORK, Dec. 14, 2020 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to […]

Read Post
December 3, 2020

eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focussed on eTheRNA’s proprietary mRNA development products and manufacturing capabilities

eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focussed on eTheRNA’s proprietary mRNA development products and manufacturing capabilities   Niel, Belgium, December 1st, 2020: eTheRNA immunotherapies NV (“eTheRNA”) today announced it has entered into a strategic cooperation and product license agreement with China Grand Pharmaceutical & Healthcare Holdings Ltd […]

Read Post
November 16, 2020

Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal

Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal Preclinical data highlights potential therapeutic action and protection against neurodegeneration Mataró, Barcelona, Spain and Gosselies, Belgium, November 16, 2020 – Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous […]

Read Post
November 3, 2020

ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors

ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors    Development of New Treatment Conferring Broad Protection Against Coronaviruses on Track   Belgium, 3 Nov 2020: ExeVir, which is developing nanobody therapies providing broad protection against viral infections, including a lead candidate for coronaviruses, today announced that Michel Kazatchkine and Stef […]

Read Post
November 2, 2020

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed – Top-Line Data Expected in Q1 2021 – NEW YORK, Nov. 2, 2020 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral […]

Read Post
November 2, 2020

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases EIB support to develop breakthrough treatments to address orphan neurodegenerative diseases with high unmet medical needs Focus on Minoryx’s lead asset, leriglitazone, a novel, disease-modifying PPAR-γ agonist Venture debt operation supported by the Investment Plan […]

Read Post
October 21, 2020

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy   – European Investment Bank and Immunic sign a financing agreement of up to €24.5 million to support the development of Immunic’s lead asset, IMU-838, in moderate COVID-19 – IMU-838 is an orally available small molecule, which, because of its […]

Read Post
October 15, 2020

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development   Ghent, Belgium – October 15, 2020 – Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications. Confo has applied its proprietary, […]

Read Post
October 9, 2020

eTheRNA extends senior management team with appointment of Michael Mulqueen as VP Business Development

eTheRNA extends senior management team with appointment of Michael Mulqueen as VP Business Development New hire will accelerate commercial development of Company’s proprietary TriMix mRNA platform for oncology and infectious disease immunotherapies   Niel, Belgium, October xx, 2020 – eTheRNA immunotherapies NV (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing immunotherapies from its proprietary mRNA […]

Read Post
September 28, 2020

Ona Therapeutics is named as one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2020

Ona Therapeutics is named as one of Fierce Biotech’s  “Fierce 15” Biotech Companies of 2020   Barcelona, Spain – 28 September 2020 – Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, today announced that it has been named by Fierce Biotech as one of 2020’s Fierce […]

Read Post
September 28, 2020

Novadip Biosciences, spin-off de l’UCLouvain et les Cliniques universitaires Saint-Luc (UCLouvain) ont réalisé une première mondiale en matière de reconstruction osseuse

Première mondiale dans le domaine de la chirurgie orthopédique : la thérapie cellulaire tridimensionnelle développée par Novadip Biosciences, spin-off de l’UCLouvain, a permis aux chirurgiens des Cliniques universitaires Saint-Luc de réparer l’os du tibia d’un jeune patient grâce à l’implant d’un greffon osseux de 18 cm³. La spin-off UCLouvain Novadip est à la pointe de la […]

Read Post
September 23, 2020

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau • Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition • Minoryx will receive an upfront and milestone payments […]

Read Post
August 20, 2020

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function   NEW YORK, Aug. 20, 2020 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced dosing of […]

Read Post
August 20, 2020

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares   NEW YORK, Aug. 10, 2020 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the closing of an […]

Read Post
August 20, 2020

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock   NEW YORK, Aug. 4, 2020 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,000,000 […]

Read Post
July 28, 2020

Fund+ Establishes ExeVir Bio with VIB and UCB to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19

Fund+ Establishes ExeVir Bio with VIB and UCB to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19 Leads Series A Financing of EUR23M to Advance Lead Novel Llama-derived Antibody into Clinical Trials ExeVir Bio’s Technology Platform has Potential to Generate Robust Antiviral Therapies Fund+ Partner Philippe Monteyne will join the Board   Belgium, […]

Read Post
July 27, 2020

Fund+ Leads EUR38 Million Series B Financing in Indigo Diabetes NV

Fund+ Leads EUR38 Million Series B Financing in Indigo Diabetes NV   o   Fund+ strengthens portfolio with medical device company developing a novel ‘invisible’ sensor for diabetes o   Jan Van den Bossche Partner at Fund+ will join the Board Belgium, 27 July 2020: Fund+, an investment firm focused on innovative European Life Sciences companies, today […]

Read Post
July 13, 2020

Aelin Therapeutics awarded €2.3 million VLAIO research grant

Aelin Therapeutics awarded €2.3 million VLAIO research grant  Funding will enable accelerated development of unique Pept™-in-based cancer therapeutics Leuven, BELGIUM – 9 July 2020 – Aelin Therapeutics NV, an emerging biotechnology company focused on the discovery and development of breakthrough Pept-in™-based therapeutics with novel modes of action to treat cancer and serious infectious diseases, today announces […]

Read Post
June 16, 2020

eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through toclinical proof of concept

eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through toclinical proof of concept Advancing oncology and infectious diseases pipeline, including new SARS-CoV-2 program  Proprietary mRNA TriMix technology provides unprecedented immune responses  Ongoing clinical trials in metastatic melanoma and breast cancer  Proprietary LNP platform for […]

Read Post
June 16, 2020

Fund+ Announces Investment in Ona Therapeutics EUR30 Million Series A financing

Fund+ Announces Investment in Ona Therapeutics EUR30 Million Series A financing   o   Fund+ building a strong and diversified oncology portfolio o   Alexandra Tolia, Partner at Fund+ will join the Board   Belgium, 16 June 2020: Fund+, an investment firm focused on innovative European Life Sciences companies, today announces that it has invested in a […]

Read Post